WHAT WE DO
Our mission at Partners Innovation Fund (“PIF”) is to create ventures that develop new drugs and technologies based on inventions originating from Partners.
In 1846, William T.G. Morton performed the first public surgery using an anesthetic at Mass. General’s surgical amphitheater.
Partners HealthCare was founded by Brigham and Women’s Hospital and Massachusetts General Hospital with a Rich Legacy Of Innovation. Partners is the largest academic research organization in the United States and a principal teaching affiliate of Harvard Medical School with an annual research expenditure of $1.6 billion. Learn more about Partners.
The Partners Innovation Fund was created in 2008 to advance new science and technology based on Partners' intellectual and financial capital. From the initial commitment of $35M from BWH and MGH, the fund has grown to $171 million through internal and external investment.
PIF invests exclusively in healthcare companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to build companies focused on drugs, devices, diagnostics and digital health.
PIF invests exclusively in healthcare sector companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics and digital health.
Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support our portfolio companies through their entire financing lifecycles.
In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies.
The Fund enjoys privileged access to the Partners intellectual property estate with the first look at newly disclosed inventions and the opportunity to work side-by-side with principal investigators across the Partners network. In addition to this privileged deal flow, we also have an unparalleled interface with clinical and scientific expertise to support evaluation and due diligence investigation.
Partners’ hospitals boasts a history of medical firsts, including the use of TNF fusion protein for the treatment of rheumatoid arthritis (Enbrel®); elucidation of PD-1 receptor biology that spawned the field of immuno-oncology therapy; the discovery of CRISPR gene-editing technology; and the targeting of EGFR gene mutations that enable high-efficacy personalized lung cancer therapy.
3 - 5